Key result
Fixed-dose new oral anticoagulants may be inadequate for obese patients (>100 kg or BMI >30 kg/m2) due to altered pharmacokinetics and their underrepresentation in major clinical trials.
Why the study?
Is the fixed dose of new oral anticoagulants adequate for obese patients (>100 kg or BMI >30 kg/m2)?
Is the fixed dose of new oral anticoagulants adequate for obese patients (>100 kg or BMI >30 kg/m2)?
This review questions the adequacy of fixed-dose NOACs in obese patients due to their underrepresentation in pivotal trials and reports of embolic events.
Answers are grounded in this paper and cite their sources.
Supports caution with fixed-dose NOACs in obese patients; leaves open need for dedicated dosing trials.
Obesity is a significant cause of morbidity and mortality, and it is becoming increasingly prevalent worldwide. Altered pharmacodynamics and pharmacokinetics of drugs in obese patients require dose adjustment according to body weight. New oral anticoagulants (NOACs), which are more frequently used for anticoagulation, are recommended to be used at a fixed dose based on data derived from phase 2 and 3 studies. However, the representation of obese patients [>100 kg or a body mass index (BMI) of >30 kg/m2] in subgroups with a small sample size and reports of various emboli cases under drug treatment have raised suspicions about the adequacy of fixed dose use. To address this issue, we analyzed several patients with a body weight of >100 kg or BMI of >30 kg/m2 participating in NOAC studies and evaluated whether these numbers were sufficient to enable an accurate recommendation of fixed dose use in obese patients.
No takes yet. Share an insight, caveat, or question.
Güler et al. (2015) conducted a review in Obesity with indication for anticoagulation (Atrial Fibrillation, VTE, Orthopedic Surgery). New oral anticoagulants (NOACs) vs. Conventional treatment (warfarin, enoxaparin) or placebo was evaluated on Efficacy (thromboembolic events) and safety (major bleeding) across multiple trials. Fixed-dose new oral anticoagulants may be inadequate for obese patients (>100 kg or BMI >30 kg/m2) due to altered pharmacokinetics and their underrepresentation in major clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: